ONO 1101

Known as: ONO-1101 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
The purpose of this study was to assess the cardiovascular effects of an ultra-short-acting beta-blocker, ONO-1101, by using… (More)
Is this relevant?
1998
1998
We investigated the effect of a new ultrashort-acting β-blocker, ONO-1101, on hemodynamic responses to isoflurane inhalation and… (More)
  • table 1
  • table 2
Is this relevant?
1998
1998
Time courses of beta-adrenoceptor-blocking actions of ONO-1101, a new cardioselective beta-blocker, were compared with those of… (More)
Is this relevant?
1997
1997
Objective: To investigate the clinical effectiveness and safety of ONO-1101, a new ultrashort-acting (half-life 3–4 min… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
1997
1997
A fertility study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague-Dawley… (More)
Is this relevant?
1997
1997
A teratogenicity study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in Sprague… (More)
Is this relevant?
1997
1997
A perinatal and postnatal study of landiolol hydrochloride (ONO-1101), a novel ultra short acting beta-blocker, was conducted in… (More)
Is this relevant?
1996
1996
Direct effects of ONO-1101 ¿(-)-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl-3-[4-[(S) -2-hydroxy-3-(2-morpholino carbonylamino… (More)
Is this relevant?
1992
1992
A novel, highly cardioselective ultra short-acting beta-blocker, ONO-1101, has been developed for application in the emergency… (More)
Is this relevant?